Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs) · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether ART alone changes complete or Partial Response compared with vincristine or Bleomycin (very low certainty).
1 finding from 1 review
RR 0.2 [0.05, 0.79]
24 participants
Very low
Complete response · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether ART alone changes complete Response compared with vincristine or Bleomycin (very low certainty).
1 finding from 1 review
RR 1.2 [0.13, 11.43]
24 participants
Very low
Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV probably leads to higher clinical response ‐ partial response compared with HAART alone (moderate certainty).
1 finding from 1 review
Complete or partial remission · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV probably leads to higher clinical response ‐ overall response (complete and partial) compared with HAART alone (moderate certainty).
1 finding from 1 review
Complete response plus partial response Length of · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Response to Tx compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 1.47 [0.87, 2.49]
36 participants
Very low
Complete/Partial Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Among Known Outcome compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 1.01 [0.81, 1.27]
30 participants
Very low
All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV showed no clear difference in mortality compared with HAART alone (moderate certainty).
1 finding from 1 review
Progressive disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV probably leads to lower progressive disease compared with HAART alone (moderate certainty).
1 finding from 1 review
Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV showed no clear difference in clinical response ‐ complete response compared with HAART alone (moderate certainty).
1 finding from 1 review
Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV probably leads to lower clinical response ‐ stable disease compared with HAART alone (moderate certainty).
1 finding from 1 review
Adverse events · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + ABV showed no clear difference in adverse events compared with HAART alone (moderate certainty).
1 finding from 1 review
Kaposi's sarcoma IRIS · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + liposomal anthracycline showed no clear difference in kaposi's sarcoma IRIS compared with HAART alone (moderate certainty).
1 finding from 1 review
All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + liposomal anthracycline showed no clear difference in mortality compared with HAART alone (moderate certainty).
1 finding from 1 review
Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Healing of ulceration · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Duration to heal oral ulcerations after initiation of treatment · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Incidence and recurrence after healing of ulcers · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + pegylated liposomal doxorubicin showed no clear difference in clinical response compared with HAART alone (moderate certainty).
1 finding from 1 review
Complete response · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Response to Tx compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 6.54 [1, 42.86]
36 participants
Very low